Tildrakizumab Efficacy by Metabolic Syndrome Status in Psoriasis: Post Hoc Analysis of 3-Year Data from the Phase 3 Resurface 1 And Resurface 2 Studies

Main Article Content

Mark G Lebwohl
Nehal N Mehta
Alice B Gottlieb
Alan M Mendelsohn

Keywords

Psoriasis, Tildrakizumab, Biologics, Efficacy, Metabolic Syndrome

Abstract

Abstract not available.

References

1) Alberti KG, et al. Circulation. 2009;120(16):1640–5.

2) Fernandez-Armenteros JM, et al. J Eur Acad Dermatol Venereol. 2019;33(1):128–35.

3) Singh S, et al. PLoS One. 2017;12(7):e0181039.

4) Langan SM, et al. J Invest Dermatol. 2012;132(3 Pt 1):556–62.

5) Talamonti M, et al. J Eur Acad Dermatol Venereol. 2018;32(10):1737–44.

6) Jacobi A, et al. Int J Dermatol. 2016;55(3):296–302.

7) Pinter A, et al. J Dermatolog Treat. 2019:1–7.

8) Reich K, et al. Lancet. 2017;390(10091):276–88.

9) National Institutes of Health. https://www.nhlbi.nih.gov/files/docs/guidelines/atp3xsum.pdf; 2001 [accessed August 18, 2018].

10) Lebwohl M. Presented at: AAD Annual Meeting 2019.

11) Leonardi C. Presented at: AAD Annual Meeting 2019.

12) Mehta N, et al. J Am Acad Dermatol. 2019;81(4 S1): AB131.